ClearPoint Neuro Q3 rev $8.9M (+9% YoY); narrows FY25 guide $36-38M; acquires IRRAS

ClearPoint Neuro, Inc.

2025-Q3 EPS reported -$0.63 vs consensus -$0.20 ▼ miss (-208.8%)

Q3 revenue $8.9M, up 9% YoY; cash $38.2M as of Sept 30, 2025.
FY2025 revenue guidance narrowed to $36M-$38M; combined 2026 with IRRAS expected $54M-$60M.
Signed agreement to acquire IRRAS Holdings; no purchase price disclosed.
New CAL preclinical facility operational; FDA 510(k) clearance for 1.5T PRISM Laser Therapy.
Active biopharma partners >60; plan to activate 35-40 specialized centers for cell/gene therapy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.